US Patent 7,686,786: Scope, Claims, Expiration, and Injection-Pen Patent Landscape

US Patent 7,686,786 protects a specific mechanical architecture for dose reduction and spring-energy management in a medication injection pen. Its central limitation is the use of dial-up and dial-down cams located on regions of the same track, with corresponding keys positioned on the same arm. The patent is directed to injection-device mechanics, not to a drug, active ingredient, formulation, or therapeutic method.

The patent was granted to Novo Nordisk A/S and is titled "Dial-down mechanism for an injection device." It issued on April 13, 2010, from US application publication US 2006/0224170 A1. Based on the apparent US filing timeline, the scheduled 20-year patent-term endpoint is in 2026, subject to any applicable patent-term adjustment or terminal disclaimer recorded by the USPTO.[1]

What does US Patent 7,686,786 protect?

The patent protects a dial-down mechanism that allows a user to reverse a dose-setting operation while controlling a torsion spring used to assist medicament injection.

The claimed mechanism requires the following core architecture:

Claim element	Required technical feature
Injection-device mechanism	A dial-down mechanism incorporated into an injection device
Energy source	A torsion spring that assists dose injection
Dose-setting member	Rotates in a first direction to set or increase a dose
Dial-up interface	A dial-up cam engages a dial-up key
Spring loading	Dial-up rotation strains the torsion spring
Reverse operation	Rotation in the opposite direction releases the torsion spring
Dial-down interface	A dial-down cam engages a dial-down key
Common track	Dial-up and dial-down cams form regions of the same track
Common arm	Dial-up and dial-down keys are both located on the same arm
Device claim	The mechanism is used in a medication delivery device
Pen claim	The medication delivery device is a handheld injection pen

The common-track and common-arm limitations distinguish the claimed structure from a system using separate tracks, separate support members, or independently mounted keys.

What is the independent claim structure?

Claim 1 is the principal mechanical claim. Claim 9 independently applies the mechanism to a medication delivery device. Claim 10 narrows the device to a handheld medication injection pen.

Claim 1: dial-down mechanism

Claim 1 requires a combination of mechanical relationships rather than merely a spring-loaded pen. A potentially relevant device must include:

A torsion spring used to assist injection.
A dose-setting member capable of rotation in two opposite directions.
A dial-up cam and dial-up key that cooperate during dose setting.
A dial-down cam and dial-down key that cooperate during reverse rotation.
Dial-up and dial-down cams forming regions of the same track.
Both keys mounted on the same arm.

The claim does not cover every pen in which the user can reduce a selected dose. It targets a particular cam-and-key arrangement that coordinates forward and reverse rotation.

Claim 9: medication delivery device

Claim 9 covers a medication delivery device containing the mechanism of claim 1. It does not independently broaden the mechanical limitations of claim 1. A device must still satisfy every limitation of claim 1 to fall within claim 9.

Claim 10: handheld injection pen

Claim 10 narrows claim 9 to a handheld medication injection pen. This claim is commercially relevant because the described architecture is most naturally implemented in reusable or disposable pen injectors.

How do claims 2 through 8 narrow the invention?

Claims 2 through 8 add alternative geometric and duplicated cam/key configurations.

Claim	Additional limitation	Scope effect
2	Dial-up cam forms part of a curved track	Excludes non-curved dial-up tracks from literal scope
3	Curved track is circular, elliptical, or parabolic	Narrows claim 2 to specified mathematical curve types
4	First and second dial-up cams	Requires two dial-up cam structures
5	First and second dial-up keys corresponding to the two cams	Requires a matched two-cam, two-key arrangement
6	Dial-down cam forms part of a V-shaped track	Narrows the dial-down geometry
7	First and second dial-down cams	Requires two dial-down cam structures
8	First and second dial-down keys corresponding to the two cams	Requires a matched two-cam, two-key arrangement

Claims 2 and 3 should be read together as nested limitations. Claim 3 requires a curved dial-up track and further specifies its shape. Claims 4 and 5 address multiple dial-up cam/key pairs. Claims 7 and 8 do the same for dial-down operation.

The dependent claims may provide narrower positions against validity challenges, but they also create more demanding infringement tests. A competing product that avoids the specific curve, V-shaped track, or dual-key configuration may fall outside those claims even if it uses the broader spring-assisted dial-down concept.

What is the key claim-construction issue?

The most important limitation is the requirement that the dial-up and dial-down cams form part of regions of the same track.

A "same track" construction could be litigated at several levels:

Whether the cams must be physically continuous.
Whether separate cam surfaces connected by an intervening region qualify.
Whether the track must be formed in one component.
Whether the track may be distributed across cooperating components.
Whether the term refers to a geometric path, a guide channel, or a functional camming surface.

The second major issue is the "same arm" limitation. A device with one arm carrying the dial-up key and another arm carrying the dial-down key would present a strong noninfringement position under the literal claim language. The analysis could change under the doctrine of equivalents, although prosecution-history estoppel and the importance of the common-arm limitation would be material.

The claim also requires that forward rotation strain the torsion spring and reverse rotation release it. A design using a compression spring, extension spring, motor, or energy storage mechanism other than the claimed torsion spring would have a potentially strong design-around position.

What formulations are protected by US 7,686,786?

None.

US 7,686,786 does not claim:

An active pharmaceutical ingredient.
A drug formulation.
A biologic.
A cartridge formulation.
A preservative system.
A dose concentration.
A method of treating a disease.
A manufacturing process for a drug substance.
A specific therapeutic indication.

The claims are device claims. The patent could affect a pen platform used to deliver insulin, GLP-1 receptor agonists, growth hormone, anticoagulants, or other medicines, but it does not create exclusivity over those products.

What is the Orange Book status of US 7,686,786?

US 7,686,786 is not, by its claim category, an Orange Book drug patent. The FDA Orange Book lists patents submitted for approved drug products, including patents covering drug substances, drug products, and approved methods of use.[2]

A mechanical injection-pen patent may be commercially important without appearing in the Orange Book. Its absence from the Orange Book means:

It generally does not create a conventional Paragraph IV certification pathway.
A generic drug applicant ordinarily would not challenge this patent through an Orange Book certification.
Patent disputes may arise through ordinary district-court litigation, supplier disputes, licensing negotiations, or device-related regulatory programs.
The patent is more likely to affect a device manufacturer, combination-product sponsor, or contract manufacturer than a conventional tablet or injectable-drug generic.

The FDA Purple Book is also not the relevant listing mechanism because this patent does not concern a biologic or biosimilar reference product.[3]

When does US Patent 7,686,786 lose exclusivity?

The patent’s expected US term ends in 2026, calculated from the relevant US filing date under the 20-year patent-term rule. The precise expiration date depends on the USPTO record for:

The earliest effective nonprovisional or PCT filing date.
Any patent-term adjustment.
Any terminal disclaimer.
Whether maintenance fees remained current.
Any correction or reexamination order affecting the patent.

The grant date does not determine expiration. The relevant date is the statutory patent-term calculation under 35 U.S.C. § 154.[4]

Event	Date or status
Earliest priority period	2005 priority period indicated in published patent records
US application publication	US 2006/0224170 A1
US grant	April 13, 2010
Patent number	US 7,686,786 B2
Scheduled term	20 years from the applicable US filing date
Expected end of term	2026, subject to USPTO term adjustment and status records

After patent expiration, the claimed mechanical architecture becomes available for practice from a patent-term perspective. Other patents in the same family, continuations, divisionals, improvement patents, or third-party patents may continue to restrict a product.

How strong is the patent estate for the claimed mechanism?

The individual patent has meaningful but narrow technical scope.

Strengths

The principal strengths are structural specificity and multiple interacting limitations:

The claim requires both forward and reverse camming.
The cam regions must belong to the same track.
The keys must be located on the same arm.
The torsion spring must be strained during dose setting and released during reverse rotation.
Claims 9 and 10 extend the mechanism to delivery devices and handheld pens.

These limitations can distinguish the invention from generic descriptions of dose dialing or spring-assisted injection.

Limitations

The same specificity narrows enforcement:

A non-torsion energy source may avoid the claims.
Separate tracks may avoid the common-track limitation.
Separate arms may avoid the common-arm limitation.
A device that permits dose reduction through a clutch, ratchet, electronic control, or axial release may avoid the claimed cam/key arrangement.
Claims 2 through 8 require additional geometries or duplicated components.

The patent is therefore strongest against a close mechanical implementation and weaker against functionally similar platforms using a different architecture.

Which companies may face relevant freedom-to-operate issues?

The relevant competitive set includes companies that design or supply pen-injector platforms, not only pharmaceutical companies. It includes Novo Nordisk, Eli Lilly, Sanofi, Ypsomed, SHL Medical, Haselmeier, Owen Mumford, and Phillips-Medisize, among others.

The risk analysis should focus on the actual mechanical source of the pen:

Company category	Principal exposure
Drug manufacturers	Combination-product and branded-device implementation
Pen-platform suppliers	Direct device patent exposure
Contract manufacturers	Component and assembly-level infringement risk
Generic drug companies	Device substitution and combination-product risk
Biosimilar sponsors	Delivery-device selection and platform licensing
Cartridge suppliers	Interface and mechanical integration issues

A manufacturer does not avoid risk merely because the active ingredient is off patent. Device patents can remain relevant after drug-substance and formulation patents expire.

Are there Paragraph IV challenges or patent litigation?

The patent’s device-focused claims do not naturally generate a standard Paragraph IV dispute. Paragraph IV certifications apply to patents listed for approved drug products in the Orange Book, not to every patent that may affect a drug-delivery device.

A litigation review should separate:

Direct infringement actions involving the patent.
Litigation involving related continuation or divisional patents.
Disputes over pen-platform licensing.
Product liability or regulatory proceedings that mention the device.
Patent challenges involving the same cam, key, spring, or dose-setting architecture.

No conclusion about current litigation status should be drawn solely from the claim text. The authoritative sources are the USPTO Patent Center file history and federal court docket records.

Are there licensing deals involving this patent?

The patent record identifies the patent owner and prosecution history, but it does not establish private licensing terms. Device-platform licenses are often granted through broader agreements covering:

A family of injection-device patents.
Manufacturing know-how.
Tooling and production rights.
Combination-product supply arrangements.
Territory-specific commercialization rights.
Improvements and successor platforms.

A public license should not be inferred from the use of a similar pen by another company. Commercial use may reflect an expired patent, a noninfringing design, a cross-license, an acquired platform, or a confidential supply agreement.

What generic launch risks exist?

The patent does not block a generic active ingredient by itself. Its commercial effect is concentrated in products that require a similar injection pen.

Potential launch scenarios include:

Launch scenario	Patent implication
Vial and syringe product	Low direct relevance to this patent
Prefilled syringe with no claimed cam system	Usually outside the claim architecture
Auto-injector using a different drive system	Potentially outside scope
Pen using torsion spring and same-track cam system	Higher infringement risk
Licensed or authorized pen platform	Risk managed contractually
New pen with separate cam tracks or arms	Possible design-around
Drug sold with a device supplied by a third party	Allocation of infringement and indemnity risk must be assessed

The patent may therefore increase development cost without preventing market entry. A competitor can redesign the mechanism, select a different supplier, or choose a non-pen presentation.

How does US 7,686,786 compare with drug and biologic patent estates?

Estate type	What it protects	Relevance of US 7,686,786
Small-molecule composition patent	Active ingredient	None
Formulation patent	Drug composition and excipients	None
Method-of-use patent	Treatment indication or dosing regimen	None
Biologic patent	Protein, antibody, or production process	None
Device patent	Injector structure and operation	Direct
Combination-product patent	Drug-device integration	Potentially adjacent
Manufacturing patent	Device assembly or component production	Potentially adjacent

This patent should be analyzed as one layer in a combination-product freedom-to-operate review. It cannot be used to estimate the full exclusivity period for a drug delivered through the pen.

Key Takeaways

US 7,686,786 is a mechanical injection-device patent assigned to Novo Nordisk A/S.
Claim 1 requires a torsion spring, opposite-direction dose-member rotation, dial-up and dial-down cams on regions of the same track, and both keys on the same arm.
Claims 9 and 10 extend the mechanism to medication delivery devices and handheld injection pens.
The patent does not protect a drug, formulation, biologic, indication, or dose.
It is not the type of patent ordinarily challenged through an Orange Book Paragraph IV certification.
The expected US patent-term endpoint is in 2026, subject to the USPTO’s final term calculation.
The strongest design-around strategies target the torsion spring, common-track, and common-arm limitations.
Device suppliers and combination-product sponsors face greater direct exposure than conventional drug manufacturers.
Related family members, continuation patents, and third-party device patents must be reviewed before concluding that a product is clear to launch.

FAQs About US Patent 7,686,786

Does US 7,686,786 cover insulin or GLP-1 drugs?

No. It covers a mechanical injection-device mechanism. It does not claim insulin, GLP-1 compounds, formulations, or treatment methods.

Can a generic drug company avoid the patent by using a vial?

Potentially. A vial-and-syringe presentation generally would not use the claimed pen mechanism, although other patents and regulatory requirements may apply.

Does the patent cover every dose-reduction feature in an injection pen?

No. The claimed device must satisfy the specific cam, key, torsion-spring, same-track, and same-arm limitations.

Is this patent relevant to biosimilar autoinjectors?

It may be relevant if a biosimilar sponsor uses a pen or delivery system with the claimed architecture. The patent itself is not a biosimilar patent and does not create biologic exclusivity.

What is the main technical design-around for this patent?

The principal design-around options are using separate cam tracks, separate support arms, a non-torsion energy source, or a dose-reduction system that does not release the torsion spring through the claimed dial-down cam and key arrangement.

References

United States Patent and Trademark Office. (2010). US Patent No. 7,686,786 B2: Dial-down mechanism for an injection device.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
35 U.S.C. § 154. Patent term.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	04077900	Oct 21, 2004

PCT Information
PCT Filed	October 20, 2005	PCT Application Number:	PCT/EP2005/011285
PCT Publication Date:	May 04, 2006	PCT Publication Number:	WO2006/045526

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E444090	⤷ Start Trial
Australia	2005298944	⤷ Start Trial
Canada	2584760	⤷ Start Trial
China	100571804	⤷ Start Trial
China	101060874	⤷ Start Trial
Germany	602005016952	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,686,786

Summary for Patent: 7,686,786